Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis.

Abstract

Primary systemic immunoglobulin light chain (AL) amyloidosis is caused by a plasma cell clone of, usually low, malignant potential that expresses CD38 molecules on their surface. Treatment of AL amyloidosis is based on the elimination of the plasma cell clone. The combination of cyclophosphamide-bortezomib-dexamethasone (CyBorD) is the most widely used and is considered a standard of care; however, complete hematologic response rates and organ response rates remain unsatisfactory. Daratumumab, an anti-CD38 monoclonal antibody, has demonstrated encouraging results, with rapid and deep responses, in patients with relapsed or refractory AL amyloidosis as monotherapy with a favorable toxicity profile. The large phase-III, randomized, ANDROMEDA study evaluated the addition of daratumumab to CyBorD in previously untreated patients with AL amyloidosis and demonstrated that addition of daratumumab can substantially improve hematologic complete response rates, survival free from major organ deterioration or hematologic progression, and organ responses. In this review, we discuss the role of daratumumab in the treatment of AL amyloidosis, its mechanism of action, and the results of ANDROMEDA study that led to the first approved therapy for AL amyloidosis.

• Authors: Foteini Theodorakakou, Meletios A Dimopoulos, Efstathios Kastritis
• Journal: Therapeutic advances in hematology (Ther Adv Hematol) Vol. 12 Pg. 20406207211058334 ( 2021) ISSN: 2040-6207 [Print] England
• PMID: 34840708 (Publication Type: Journal Article, Review)
• Copyright: © The Author(s), 2021.